Modafinil Disease Interactions
There are 9 disease interactions with modafinil.
- Cardiac disease
- Hypertension
- Liver disease
- Psychiatric disorders
- Bipolar disorders
- Psychotic disorders
- Renal dysfunction
- Seizure disorders
- Cardiovascular
CNS stimulants (applies to modafinil) cardiac disease
Major Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease, Pheochromocytoma, Hyperthyroidism
The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc. Sudden death has been reported in adults and children taking CNS stimulant treatment. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias, and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam, and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc (2001):
- "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation (2001):
- "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
- "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Concerta (methylphenidate)." Alza (2002):
- "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
- "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
- "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
CNS stimulants (applies to modafinil) hypertension
Major Potential Hazard, Moderate plausibility.
CNS stimulants have been shown to increase blood pressure, and their use might be contraindicated in patients with severe/uncontrolled hypertension. Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions. All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc (2001):
- "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation (2001):
- "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
- "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Concerta (methylphenidate)." Alza (2002):
- "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
- "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
- "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
CNS stimulants (applies to modafinil) liver disease
Major Potential Hazard, Moderate plausibility.
In general, CNS stimulants are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly. Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury. Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc (2001):
- "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation (2001):
- "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
- "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Concerta (methylphenidate)." Alza (2002):
- "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
- "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
CNS stimulants (applies to modafinil) psychiatric disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Depression
The use of CNS stimulants can cause psychotic or manic symptoms, suicidal ideation, and aggression, and can exacerbate symptoms of behavior disturbance and thought disorder. Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, especially during treatment initiation and at times of dose changes. Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder. All patients receiving treatment should be screened for bipolar disease prior to initiation. If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered. CNS stimulants are contraindicated in patients with marked agitation or anxiety.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc (2001):
- "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation (2001):
- "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
- "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Concerta (methylphenidate)." Alza (2002):
- "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
- "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
- "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc (2023):
- "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
CNS stimulants (applies to modafinil) bipolar disorders
Moderate Potential Hazard, Moderate plausibility.
CNS stimulants may induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression). Close monitoring is recommended when using these agents in patients with bipolar disorders.
References
- "Product Information. Cylert (pemoline)." Abbott Pharmaceutical (2001):
- "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals (2001):
- "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
- "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
- "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim (2001):
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
- "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
CNS stimulants (applies to modafinil) psychotic disorders
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis
CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. Close monitoring is recommended when using these agents in patients with psychotic disorders.
References
- "Product Information. Cylert (pemoline)." Abbott Pharmaceutical (2001):
- "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals (2001):
- "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
- "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
- "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim (2001):
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
- "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- "Product Information. Fintepla (fenfluramine)." Zogenix, Inc (2020):
CNS stimulants (applies to modafinil) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response. The dosage should be adjusted accordingly.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc (2001):
- "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
CNS stimulants (applies to modafinil) seizure disorders
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures
Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures. These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures. Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures. If seizures appear, therapy should be discontinued.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc (2001):
- "Product Information. Cylert (pemoline)." Abbott Pharmaceutical (2001):
- "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
- "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Concerta (methylphenidate)." Alza (2002):
- "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
- "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
Modafinil (applies to modafinil) cardiovascular
Moderate Potential Hazard, Low plausibility. Applicable conditions: Cardiovascular Disease, Cerebral Vascular Disorder
In clinical trials, a few patients treated with modafinil developed chest pain, palpitations, dyspnea and transient ischemic T-wave changes in association with mitral valve prolapse or left ventricular hypertrophy. The manufacturer recommends that modafinil not be used in patients with a history of left ventricular hypertrophy or ischemic ECG changes, chest pain, arrhythmia or other clinically significant manifestations of mitral valve prolapse in association with central nervous system (CNS) stimulant use. In addition, caution is advised in patients with cardiovascular disease due to other causes, particularly hypertension and/or a recent history of myocardial infarction or unstable angina, since the use of modafinil has not been evaluated in such patients.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc (2001):
Modafinil drug interactions
There are 463 drug interactions with modafinil.
Modafinil alcohol/food interactions
There are 2 alcohol/food interactions with modafinil.
More about modafinil
- modafinil consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (510)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Support group
- Drug class: CNS stimulants
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.